Yahoo Web Search

Search results

1. pmc.ncbi.nlm.nih.gov › articles › PMC10361863Discordance of PIK3CA mutational status between primary and ...

   pmc.ncbi.nlm.nih.gov › articles › PMC10361863

   In contrast, PIK3CA mutations have been detected in 28% of HR + /HER2- metastatic BC patients and correlated with worse overall survival as well as resistance to chemo- and endocrine therapy . However, none of the aforementioned studies have assessed PIK3CA mutations in matched primary and metastatic tumors. When evaluating the discordance ...

2. Videos

   • 

     3:06

     youtube.com

     Why Do Cancers Have PIK3CA Mutations and How Can They Be Targeted for Cancer Treatment?

     20 Sep 2023

     587 views

   • 

     1:58

     youtube.com

     Dr. Tolaney on Presence of PIK3CA and ESR1 Mutations in MONARCH 2 Trial in Breast Cancer

     25 Apr 2019

     1.6K views

   • 

     12:55

     youtube.com

     Molecular Tumor Board Series - Breast Cancer with ESR1 and PIK3CA mutations

     28 Nov 2022

     659 views

   View all

3. www.nature.com › articles › s41598/020/74086-wPIK3CA mutation enrichment and quantitation from blood and ...

   www.nature.com › articles › s41598/020/74086-w

   Oct 13, 2020 · PIK3CA is one of the two most frequently mutated genes in breast cancers, occurring in 30–40% of cases. Four frequent ‘hotspot’ PIK3CA mutations (E542K, E545K, H1047R and H1047L) account for...

   • Author: Ieva Keraite, Ieva Keraite, Virginia Alvarez-Garcia, Virginia Alvarez-Garcia, Isaac Garcia-Murillas,...

   • Publish Year: 2020

4. www.sciencedirect.com › science › articleHighly consistency of PIK3CA mutation spectrum between ...

   www.sciencedirect.com › science › article

   Jul 15, 2024 · Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations are associated with drug resistance and prognosis in lung cancer; however, the consistency and clinical value of PIK3CA mutations between tissue and liquid samples are unknown.

5. www.nature.com › articles › s41598/021/02903-xDiscordance of PIK3CA and TP53 mutations between breast ...

   www.nature.com › articles › s41598/021/02903-x

   Dec 7, 2021 · We found PIK3CA mutations as the second most common mutation after TP53 in matched pairs of TNBC with 18% PIK3CA mutations all concordant in PTs and BMs.

   • Author: Anna Thulin

6. www.nature.com › articles › s41598/024/62664-1PIK3CA mutations in endocrine-resistant breast cancer - Nature

   www.nature.com › articles › s41598/024/62664-1

   May 31, 2024 · Mutations in the phosphatidylinositol bisphosphate 3-kinase (PI3K) catalytic subunit encoded by PIK3CA is a proposed resistance mechanism and a pharmacological target in the clinical setting....

7. bmccancer.biomedcentral.com › articles › 10PIK3CA mutation status, progression and survival in advanced ...

   bmccancer.biomedcentral.com › articles › 10

   • Cached

   Sep 21, 2022 · In the present study, we compared progression-free survival (PFS) and overall survival (OS) by PIK3CA status across studies conducted among patients with HR + /HER2- mBC, with adjustment for potential confounding or moderating effects of treatment type and mutation testing method.

8. People also ask

   Where are PIK3CA mutations found?

   • PIK3CA mutations were observed in 8.2% (94 of 1,144) of the TCGA dataset. Most mutations were missense mutations which are located in exon 9 (c.1633G > A E545K, E542K c.1624G > A) and exon 20 (c.3140A > G, H1047R), accounting for 26.7% (26/94), 20.2% (19/94), and 6.4% (6/94), respectively.

   Full article: The Study of PIK3CA Hotspot Mutations and Co-Occurring

   www.tandfonline.com/doi/full/10.2147/OTT.S468352

   See all results for this question

   Are PIK3CA mutations a pharmacological target in endocrine-resistant BC?

   • Mutations in the phosphatidylinositol bisphosphate 3-kinase (PI3K) catalytic subunit encoded by PIK3CA is a proposed resistance mechanism and a pharmacological target in the clinical setting. Here we explore the frequency of PIK3CA mutations in endocrine-resistant BC before and during treatment and correlate to clinical features.

   PIK3CA mutations in endocrine-resistant breast cancer - Nature

   www.nature.com/articles/s41598-024-62664-1

   See all results for this question

   Can PIK3CA mutations be enriched?

   • To evaluate the achievable mutant allele enrichment of PIK3CA mutations, we used genomic DNA from CAL-51, MCF-7, T-47D and EFM-19 cells known to carry the most common PIK3CA hotspot mutations—E542K, E545K, H1047R and H1047L respectively.

   PIK3CA mutation enrichment and quantitation from blood and

   www.nature.com/articles/s41598-020-74086-w

   See all results for this question

   What are the PIK3CA mutations in breast cancer?

   • Further, a study that compared the PIK3CA mutations in all publicly available datasets of breast cancers, including 6477 samples from 10 studies, showed the mutations Glu110del, Asn345Lys, Gln546Lys, Glu726Lys, and Gly1049Arg, which are also present in our cohort 21.

   PIK3CA mutations in endocrine-resistant breast cancer - Nature

   www.nature.com/articles/s41598-024-62664-1

   See all results for this question

   Which PIK3CA mutations are common in patients with NSCLC?

   • Common hotspot mutations in PIK3CA were found in exon 9 (c.1633G > A, E545K, and c.1624G > A, E542K) and exon 20 (c.3140A > G, H1047R) in all cohorts. Co-occurring mutations of PIK3CA with EGFR, KRAS, and TP53 have been frequently observed in patients with NSCLC, with different percentages in these datasets generated by different background.

   Full article: The Study of PIK3CA Hotspot Mutations and Co-Occurring

   www.tandfonline.com/doi/full/10.2147/OTT.S468352

   See all results for this question

   Are PIK3CA mutations discordant between primary and corresponding metastatic disease?

   • Dupont Jensen, J. et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin. Cancer Res. 17 (4), 667–677 (2011). Morgan, A. J., Giannoudis, A. & Palmieri, C. The genomic landscape of breast cancer brain metastases: A systematic review. Lancet Oncol. 22 (1), e7–e17 (2021).

   Discordance of PIK3CA and TP53 mutations between breast cancer ... …

   www.nature.com/articles/s41598-021-02903-x

   See all results for this question

9. www.tandfonline.com › doi › fullFull article: The Study of PIK3CA Hotspot Mutations and Co ...

   www.tandfonline.com › doi › full

   Sep 11, 2024 · PIK3CA mutations were observed in 8.2% (94 of 1,144) of the TCGA dataset. Most mutations were missense mutations which are located in exon 9 (c.1633G > A E545K, E542K c.1624G > A) and exon 20 (c.3140A > G, H1047R), accounting for 26.7% (26/94), 20.2% (19/94), and 6.4% (6/94), respectively.